查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1631159

神經內分泌腫瘤治療市場規模、佔有率、趨勢分析報告：按類型、產品、地點、最終用途、地區和細分市場進行預測，2025 年至 2030 年

Neuroendocrine Tumor Treatment Market Size, Share & Trends Analysis Report By Type (Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma), By Product, By Site, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

神經內分泌腫瘤治療市場的成長與趨勢

根據Grand View Research, Inc.的新報告，到2030年全球神經內分泌腫瘤治療市場規模預計將達37.3億美元。

預計 2025 年至 2030 年間，該市場的複合年成長率將達到 6.0%。預計在預測期內，類癌瘤盛行率的增加將推動市場的發展。推動市場發展的另一個因素是各製藥公司在臨床試驗方面投入大量資金來開發新產品。

例如，諾華公司擁有最多的臨床試驗，其次是輝瑞公司和益普生製藥公司。此外，治療神經內分泌腫瘤的治療方法技術進步預計將在未來幾年推動市場成長。這些包括採用 Ga標記的生長抑制素的 PET 影像、標靶藥物治療和蛋白酪氨酸激酶治療。例如，諾華公司的Lutathera是第一個獲得FDA核准的放射性核苷酸療法。

神經內分泌腫瘤治療市場報告重點

  • 隨著類癌瘤盛行率不斷上升以及治療技術不斷進步，類癌瘤領域將佔據市場主導地位，2024 年的收入佔有率為 24.3%。
  • 生長抑制素類似物 (SSA) 部門在 2024 年的收入佔有率方面佔據了市場主導地位，因為它們已被證明可有效控制與神經內分泌腫瘤相關的症狀。
  • 小腸部分佔據市場主導地位，佔據 2024 年最大的收益佔有率。
  • 2024 年，醫院部門佔據市場主導地位，收益佔有率最大，這得益於醫院為複雜的神經內分泌腫瘤病例提供的全面護理。
  • 北美神經內分泌腫瘤治療市場佔據全球市場主導地位，2024年的收益佔有率為42.1%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 神經內分泌腫瘤治療市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析 – 波特五力分析
    • PESTLE分析

第 4 章神經內分泌腫瘤治療市場：按類型分類的商業分析

  • 2024 年及 2030 年類型市場佔有率
  • 類型細分儀表板
  • 2018 年至 2030 年按類型分類的市場規模、預測與趨勢分析
  • 腦膜瘤
  • 腎上腺癌
  • 類癌腫瘤
  • 副神經節瘤
  • 嗜鉻細胞瘤
  • 其他

第5章神經內分泌腫瘤治療市場：產品業務分析

  • 2024 年及 2030 年產品市場佔有率
  • 產品細分儀表板
  • 2018 年至 2030 年按產品分類的市場規模、預測與趨勢分析
  • 生長抑制素類似物 (SSA)
  • 標靶治療
  • 其他

第 6 章神經內分泌腫瘤治療市場：基於站點的商業分析

  • 2024 年及 2030 年零件市場佔有率
  • 身體部位細分儀表板
  • 2018 年至 2030 年按身體部位分類的市場規模、預測與趨勢分析
  • 肺
  • 胰臟
  • 冒號
  • 小腸
  • 直腸
  • 胃
  • 其他

7. 神經內分泌腫瘤治療市場-最終用途業務分析

  • 2024 年及 2030 年終端用途市場佔有率
  • 最終用途細分儀表板
  • 2018 年至 2030 年按最終用途分類的市場規模、預測和趨勢分析
  • 醫院
  • 診所
  • 其他

第 8 章神經內分泌腫瘤治療市場：按地區分類的估計和趨勢

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 按國家/地區，2018 年至 2030 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區，2018 年至 2030 年
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 新加坡
  • 拉丁美洲
    • 按國家/地區，2018 年至 2030 年
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 按國家/地區，2018 年至 2030 年
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Novartis AG
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Boehringer Ingelheim International GmbH
    • Hutchison MediPharma Limited.
    • AVEO Pharmaceuticals, Inc.
    • Ipsen Pharma.
    • Eli Lilly and Company.
    • Exelixis, Inc.
    • Jubilant Pharmova Limited
Product Code: GVR-2-68038-624-0

Neuroendocrine Tumor Treatment Market Growth & Trends:

The global neuroendocrine tumor treatment market size is expected to reach USD 3.73 billion by 2030, according to a new report by Grand View Research, Inc. The market is estimated to register a CAGR of 6.0% from 2025 to 2030. Increasing pervasiveness of carcinoid tumors is expected to drive the market over the forecast period. Heavy investment in clinical trials by various pharmaceutical companies to develop novel products is another factor propelling the market development.

For instance, Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma. Moreover, technological advancements in therapies to treat neuroendocrine tumors are anticipated to fuel the market growth over the coming years. Some of these include PET imaging with Ga labeled Somatostatin, targeted drug therapies, and tyrosine kinase therapies. For instance, Lutathera by Novartis AG received FDA approval for the first ever radionucleotide therapy.

Neuroendocrine Tumor Treatment Market Report Highlights:

  • The carcinoid tumors segment dominated the market with a revenue share of 24.3% in 2024, driven by the increasing prevalence of carcinoid tumors and advancements in treatment methodologies.
  • The Somatostatin Analogs (SSAs) segment dominated the market with the largest revenue share in 2024, attributed to their proven efficacy in managing symptoms associated with neuroendocrine tumors.
  • The small intestine segment dominated the market with the largest revenue share in 2024, attributed to the higher incidence rates of neuroendocrine tumors originating from this site.
  • The hospitals segment dominated the market with the largest revenue share in 2024, driven by the comprehensive care offered by hospitals for complex cases of neuroendocrine tumors.
  • North America neuroendocrine tumor treatment market dominated the global market with a revenue share of 42.1% in 2024, driven by high healthcare expenditure coupled with advanced medical infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Product
    • 1.2.3. Site
    • 1.2.4. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Neuroendocrine Tumor Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Neuroendocrine Tumor Treatment Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 4.4. Meningiomas
    • 4.4.1. Meningiomas Market, 2018 - 2030 (USD Billion)
  • 4.5. Adrenal Cancer
    • 4.5.1. Adrenal Cancer Market, 2018 - 2030 (USD Billion)
  • 4.6. Carcinoid Tumors
    • 4.6.1. Carcinoid Tumors Market, 2018 - 2030 (USD Billion)
  • 4.7. Paraganglioma
    • 4.7.1. Paraganglioma Market, 2018 - 2030 (USD Billion)
  • 4.8. Pheochromocytoma
    • 4.8.1. Pheochromocytoma Market, 2018 - 2030 (USD Billion)
  • 4.9. Others
    • 4.9.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 5. Neuroendocrine Tumor Treatment Market: Product Business Analysis

  • 5.1. Product Market Share, 2024 & 2030
  • 5.2. Product Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Billion)
  • 5.4. Somatostatin Analogs (SSAs)
    • 5.4.1. Somatostatin Analogs (SSAs)Market, 2018 - 2030 (USD Billion)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Neuroendocrine Tumor Treatment Market: Site Business Analysis

  • 6.1. Site Market Share, 2024 & 2030
  • 6.2. Site Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Site, 2018 to 2030 (USD Billion)
  • 6.4. Lung
    • 6.4.1. Lung Market, 2018 - 2030 (USD Billion)
  • 6.5. Pancreas
    • 6.5.1. Pancreas Market, 2018 - 2030 (USD Billion)
  • 6.6. Colon
    • 6.6.1. Colon Market, 2018 - 2030 (USD Billion)
  • 6.7. Small Intestine
    • 6.7.1. Small Intestine Market, 2018 - 2030 (USD Billion)
  • 6.8. Rectum
    • 6.8.1. Rectum Market, 2018 - 2030 (USD Billion)
  • 6.9. Stomach
    • 6.9.1. Stomach Market, 2018 - 2030 (USD Billion)
  • 6.10. Others
    • 6.10.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. Neuroendocrine Tumor Treatment Market: End Use Business Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. End Use Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Billion)
  • 7.4. Hospitals
    • 7.4.1. Hospitals Market, 2018 - 2030 (USD Billion)
  • 7.5. Clinics
    • 7.5.1. Clinics Market, 2018 - 2030 (USD Billion)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 8. Neuroendocrine Tumor Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.6.7. Singapore
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Singapore Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 8.8. MEA
    • 8.8.1. MEA Neuroendocrine Tumor Treatment Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Neuroendocrine Tumor Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis AG
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Type Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Bristol-Myers Squibb Company
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Type Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Pfizer Inc.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Type Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Boehringer Ingelheim International GmbH
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Type Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Hutchison MediPharma Limited.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Type Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. AVEO Pharmaceuticals, Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Type Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Ipsen Pharma.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Type Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Eli Lilly and Company.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Type Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Exelixis, Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Type Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Jubilant Pharmova Limited
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Type Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global neuroendocrine tumor treatment market, by region, 2018 - 2030 (USD Billion)
  • Table 4 Global neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 5 Global neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 6 Global neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 7 Global neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 8 North America neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 9 North America neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 10 North America neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 11 North America neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 12 North America neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 13 U.S. neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 14 U.S. neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 15 U.S. neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 16 U.S. neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 17 Canada neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 18 Canada neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 19 Canada neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 20 Canada neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 21 Mexico neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 22 Mexico neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 23 Mexico neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 24 Mexico neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 25 Europe neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 26 Europe neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 27 Europe neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 28 Europe neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 29 Europe neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 30 UK neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 31 UK neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 32 UK neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 33 UK neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 34 Germany neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 35 Germany neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 36 Germany neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 37 Germany neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 38 France neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 39 France neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 40 France neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 41 France neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 42 Italy neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 43 Italy neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 44 Italy neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 45 Italy neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 46 Spain neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 47 Spain neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 48 Spain neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 49 Spain neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 50 Norway neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 51 Norway neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 52 Norway neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 53 Norway neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 54 Denmark neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 55 Denmark neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 56 Denmark neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 57 Denmark neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 58 Sweden neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 59 Sweden neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 60 Sweden neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 61 Sweden neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 62 Asia Pacific neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 63 Asia Pacific neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 64 Asia Pacific neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 65 Asia Pacific neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 66 Asia Pacific neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 67 Japan neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 68 Japan neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 69 Japan neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 70 Japan neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 71 China neuroendocrine tumor treatment market, by type, 2018-2030 (USD Billion)
  • Table 72 China neuroendocrine tumor treatment market, by product, 2018-2030 (USD Billion)
  • Table 73 China neuroendocrine tumor treatment market, by site, 2018-2030 (USD Billion)
  • Table 74 China neuroendocrine tumor treatment market, by end use, 2018-2030 (USD Billion)
  • Table 75 India neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 76 India neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 77 India neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 78 India neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 79 Australia neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 80 Australia neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 81 Australia neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 82 Australia neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 83 South Korea neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 84 South Korea neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 85 South Korea neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 86 South Korea neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 87 Singapore neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 88 Singapore neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 89 Singapore neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 90 Singapore neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 91 Latin America neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 92 Latin America neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 93 Latin America neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion
  • Table 94 Latin America neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion
  • Table 95 Latin America neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion
  • Table 96 Brazil neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 97 Brazil neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 98 Brazil neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 99 Brazil neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 100 Argentina neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 101 Argentina neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 102 Argentina neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 103 Argentina neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 104 Middle East & Africa neuroendocrine tumor treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 105 Middle East & Africa neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 106 Middle East & Africa neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 107 Middle East & Africa neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 108 Middle East & Africa neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 109 South Africa neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 110 South Africa neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 111 South Africa neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 112 South Africa neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 113 Saudi Arabia neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 114 Saudi Arabia neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 115 Saudi Arabia neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 116 Saudi Arabia neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 117 UAE neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 118 UAE neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 119 UAE neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 120 UAE neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 121 Kuwait neuroendocrine tumor treatment market, by type, 2018 - 2030 (USD Billion)
  • Table 122 Kuwait neuroendocrine tumor treatment market, by product, 2018 - 2030 (USD Billion)
  • Table 123 Kuwait neuroendocrine tumor treatment market, by site, 2018 - 2030 (USD Billion)
  • Table 124 Kuwait neuroendocrine tumor treatment market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Neuroendocrine tumor treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Type outlook (USD Billion)
  • Fig. 10 Product outlook (USD Billion)
  • Fig. 11 Site outlook (USD Billion)
  • Fig. 12 End Use outlook (USD Billion)
  • Fig. 13 Competitive landscape
  • Fig. 14 Neuroendocrine tumor treatment market dynamics
  • Fig. 15 Neuroendocrine tumor treatment market: Porter's five forces analysis
  • Fig. 16 Neuroendocrine tumor treatment market: PESTLE analysis
  • Fig. 17 Neuroendocrine tumor treatment market: Type segment dashboard
  • Fig. 18 Neuroendocrine tumor treatment market: Type market share analysis, 2024 & 2030
  • Fig. 19 Meningiomas market, 2018 - 2030 (USD Billion)
  • Fig. 20 Adrenal Cancer market, 2018 - 2030 (USD Billion)
  • Fig. 21 Carcinoid Tumors market, 2018 - 2030 (USD Billion)
  • Fig. 22 Paraganglioma market, 2018 - 2030 (USD Billion)
  • Fig. 23 Pheochromocytoma market, 2018 - 2030 (USD Billion)
  • Fig. 24 Others market, 2018 - 2030 (USD Billion)
  • Fig. 25 Neuroendocrine tumor treatment market: Product segment dashboard
  • Fig. 26 Neuroendocrine tumor treatment market: Product market share analysis, 2024 & 2030
  • Fig. 27 Somatostatin analogs (SSAs) market, 2018 - 2030 (USD Billion)
  • Fig. 28 Targeted therapy market, 2018 - 2030 (USD Billion)
  • Fig. 29 Others market, 2018 - 2030 (USD Billion)
  • Fig. 30 Neuroendocrine tumor treatment market: Site segment dashboard
  • Fig. 31 Neuroendocrine tumor treatment market: Site market share analysis, 2024 & 2030
  • Fig. 32 Lung market, 2018 - 2030 (USD Billion)
  • Fig. 33 Pancreas market, 2018 - 2030 (USD Billion)
  • Fig. 34 Colon market, 2018 - 2030 (USD Billion)
  • Fig. 35 Small Intestine market, 2018 - 2030 (USD Billion)
  • Fig. 36 Rectum market, 2018 - 2030 (USD Billion)
  • Fig. 37 Stomach market, 2018 - 2030 (USD Billion)
  • Fig. 38 Others market, 2018 - 2030 (USD Billion)
  • Fig. 39 Neuroendocrine tumor treatment market revenue, by region
  • Fig. 40 Regional marketplace: Key takeaways
  • Fig. 41 North America neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 42 U.S. country dynamics
  • Fig. 43 U.S. neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 44 Canada country dynamics
  • Fig. 45 Canada neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 46 Mexico country dynamics
  • Fig. 47 Mexico neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 48 Europe neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 49 UK country dynamics
  • Fig. 50 UK neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 51 Germany country dynamics
  • Fig. 52 Germany neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 53 France country dynamics
  • Fig. 54 France neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 55 Italy country dynamics
  • Fig. 56 Italy neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 57 Spain country dynamics
  • Fig. 58 Spain neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 59 Norway country dynamics
  • Fig. 60 Norway neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 61 Denmark country dynamics
  • Fig. 62 Denmark neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion
  • Fig. 63 Sweden country dynamics
  • Fig. 64 Sweden neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 65 Asia Pacific neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 66 Japan country dynamics
  • Fig. 67 Japan neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 68 China country dynamics
  • Fig. 69 China neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 70 India country dynamics
  • Fig. 71 India neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 72 South Korea country dynamics
  • Fig. 73 South Korea neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 74 Australia country dynamics
  • Fig. 75 Australia neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 76 Singapore country dynamics
  • Fig. 77 Singapore neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 78 Latin America neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 79 Brazil country dynamics
  • Fig. 80 Brazil neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 81 Argentina country dynamics
  • Fig. 82 Argentina neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 83 MEA neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 84 South Africa country dynamics
  • Fig. 85 South Africa neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 86 Saudi Arabia country dynamics
  • Fig. 87 Saudi Arabia neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 88 UAE country dynamics
  • Fig. 89 UAE neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 90 Kuwait country dynamics
  • Fig. 91 Kuwait neuroendocrine tumor treatment market, 2018 - 2030 (USD Billion)
  • Fig. 92 Company categorization
  • Fig. 93 Company market position analysis
  • Fig. 94 Strategic framework